In addition to the Prime line, Seasonic has the Vertex, Focus, Core, and B12 series of PSUs. Seasonic has sent over one of its newest ATX 3.0 PSUs, the Focus GX-1000 ATX 3.0 PSU, for review.

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to $550.00. Andrew Fein has given his Buy rating due ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

The companies will focus on next-generation gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. Credit: da-kuk via Getty Images. Vertex Pharmaceuticals and Orna ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.